Prostate cancer (PrCa) is the second most common malignancy in men 1 . More than 50% of advanced prostate cancers display the TMPRSS2-ERG fusion 2 . Despite extensive cancer genome/transcriptome 2-4 and phosphoproteome 5 data, little is known about the impact of mutations and altered transcription on regulatory networks in the PrCa of individual patients.
and factors involved in DNA repair and chromatin methylation, or cell cycle control. One of the caveats in all these studies was that, with a few exceptions 9, 12 , information was generally compiled from large numbers of tumors from different patients. Thus, while enabling identification of predominant mutations, these studies did not reveal the spectrum of aberrations that existed in individual patients' prostates at diagnosis. All these aberrations may affect different regulatory pathways and their added, possibly synergistic action may be critical for malignancy and tumor progression. Indeed, restoring a normal state will require the correction of a highly complex and dynamically regulated system of interactive multicomponent networks which are deregulated in disease 13 . Towards this goal, the identification of aberrant networks and their inherent hierarchies is essential to design patient-selective therapeutic interventions through generic or key factor-specific modulation of the affected pathways.
We chose prostate cancer as a solid tumor paradigm to integrate patient-specific differential expressed (DEGs) and mutated genes, using information from protein-protein interaction and gene-regulatory network databases 6,7 (Fig. 1a ) to generate patient-specific cancer-modified networks. Extensively characterized normal and tumor frozen punch biopsies from the same prostate were obtained from radical prostatectomy specimens of non-treated patients. 15 primary ERG-positive tumors (T) and matched normal tissue (N) were selected by expert pathologists on the basis that consecutive sections of the same biopsy differed only minimally in tumor cellularity (>80% tumor cells), while the sections of N biopsies from the same prostate had 0% tumor cells. With one exception of patient 14 (P14), the proportion of infiltrating lymphocytes relative to tumor cells was close to 0%, only occasionally rare scattered lymphocytes were observed in the stroma. The tumor sections of P14 showed up to 25% (areabased) mononuclear immune cells. Immunohistochemistry and RNA-seq confirmed ERG overexpression relative to the matched N samples and all samples revealed increased androgen receptor (AR) levels (Fig. 1b, c) .
Whole-exome sequencing (WES, Supplementary Table 1 ) and subsequent calling of variants by MuTect2 revealed between 49 and 114 mutations in each cancer relative to the corresponding normal prostate tissue; only mutations predicted to have high or moderate impact were considered subsequently (Supplementary File 1). Intriguingly, in addition to classical mutations, for example in MYC, TP53, PTEN or components of the PI3K and WNT pathways 2, 9, 14 , unreported patient-specific mutations were observed in all samples (Supplementary Table 2; for validations see Extended Data Fig. 1 ). In P1 three hitherto unreported somatic mutations affected the putative tumor suppressors BANP 15 , FEZ1 16, 17 (Fig. 1d ) and TINAGL1, which interferes with both integrin and EGFR signaling 18 . We also found novel mutations in MAPK7 (R400H) in P9, Annexin A1 (ANXA1, frameshift deletion; P11) and a TET2 mutation that truncates the protein and renders it non-functional ( Fig. 1d; P14 ). These novel somatic mutations were seen only in single patients. However, the nature of the mutations, often truncating proteins of functional importance, is likely to have a significant impact in the individual case. Indeed, the ability of TINAGL1 to inhibit progression and metastasis of triplenegative breast cancer 18 , provides strong rational for such personalized genomic analysis. Our data underscores the recent notion that "significantly mutated genes" in PrCa may occur frequencies of only a few percent 19 .
Mutations in regulatory elements (e.g., enhancers) and factors (e.g., transcription factors, epigenetic modulators, enzymes) can affect a plethora of pathways. To integrate these effects in the network analysis, we performed duplicate high-throughput strand-specific paired-end total RNA sequencing after ribosomal RNA depletion from matched T and N biopsy sections. As expected, T vs. N analysis of the RNA-seq datasets identified tumor-specific differentially expressed genes (TS-DEGs; Supplementary File 2) with diverse functionalities, comprising (i) cancer-specific deregulated proto-oncogenes like c-MYC (all except P6, P11, P13) but also (ii) pleiotropic factors like the serine protease KLK4 (P4, P10, P14, P15), a regulator of AR and the PI3K/AKT/mTOR pathway 20 and of protease-activated receptors 21 . Notably, deletion of KLK4 impairs PrCa growth 20 . Moreover, (iii) epigenetic modifiers like JMJD6 (P14), KDM4B (P5), KDM6A (P2, P8), KDM6B (P6, P9), TET3 (P12, P14), KAT2A (P3), KAT6A (P2) or HDAC9 (P2-5, P7-11, P13-15) were differentially expressed in certain tumors. In addition to protein-coding genes, also the expression of (iv) certain regulatory RNAs was altered in tumors [micro-RNAs (miRs), as well as long non-coding RNA (lncRNAs); for annotated miRs and lncRNAs, see Supplementary   Table 3 ]. Of note, the p53-inducible lncRNA NEAT, a promising therapeutic target whose ablation generates synthetic lethality with chemotherapy and p53 reactivation therapy 22, 23 , was over-expressed in 7/15 PrCa samples. A prominent ERG binding site in VCaP and in normal prostate epithelial RWPE-1 cells about 4.6kb upstream of the NEAT transcriptional start site may account for this deregulation (see Methods). The androgen-responsive lncRNA ARLNC1 24 was up-regulated in 9/15 paired samples but down-regulated in P5. HOTTIP, a component of H3K4 methyltransferase complexes 25 that can act as AR co-activator 26 and was reported as negatively androgen-regulated lncRNA 24 in prostate cancer cells, was downregulated in 9/15 PrCa samples. This included several, but not all of those with up-regulated ARLNC1. A similar divergence was seen with putative tumor suppressor and oncogenic miRNAs that are actively considered for clinical development 27 . For example, the RNA levels of tumor-suppressor miR34a were decreased in three samples (P10, P13 and P15) but increased in P4 and not affected in 11 other samples. MiR222, which displays targetable oncoMir characteristics in liver, pancreas and lung tumors 27, 28 , was unexpectedly down-regulated in 8/15 PrCa samples. Together, these vastly divergent genetic mutations and altered, often counter-intuitive gene expression patterns revealed the need to decipher for each individual patient the complexity of the deregulated systems to identify key targets in critical signaling pathways and/or key nodes in (sub)networks for concomitant intervention at several functionally different levels to generate synergistic effects.
As a first step towards the integration of the various deregulated functions within each tumor, we performed a patient-centered pathways enrichment analysis for TS-DEGs using Panther 29 in the GenCodis3 environment 30 . While this analysis revealed several pathways commonly deregulated in PrCa of several patients -particularly cadherin, Wnt and integrin signaling -it also demonstrated that in each patient different sets of pathways were deregulated. Indeed, P5 and P6 had, respectively, the most and least severely affected PrCa in terms of numbers of deregulated pathways ( Fig. 2 ; Extended Data Fig. 2 shows additional 52 patients from the TCGA repository). Moreover, different numbers and components of a commonly deregulated pathway were altered in different patients, yielding different p-values. As pointed out previously 14 , while genetic mutations of core Wnt pathway components are rare in PrCa, abnormal expression of −catenin is frequent, suggesting that this deregulation occurs indirectly.
Genes never function in isolation but rather in a highly complex physiological context, which can be illustrated by their "communication" with other cellular components. To gain a more precise insight into the altered "communication" by patient-specific gene deregulations and mutations, we re-constructed "master networks" from all deregulated for each prostate cancer by integrating the connectivities provided by the STRING protein-protein and CellNet transcription factor-target gene interaction databases; in addition, we integrated all mutated genes and identified putative ERG and AR target genes by cognate binding sites in the vicinity of Fig. 4a, b ). Even more strikingly, the genes of several key signaling factors (PAK1, CREM) and of the epigenetic modulator SMARCD3 have apparently acquired ERG binding capability in their promoter regions during tumorigenesis (for SMARCC1, see Extended Data Fig. 4c ), as it was reported for the ERG-mediated repression of checkpoint kinase 1 31 . In contrast, P6 showed a very small number of deregulated components of the core Wnt pathway (Fig. 3b ), comprising three upregulated FZD receptors along with the cognate WNT2B ligand and WNT2 which acquired ERG binding near the TSS in VCaP cells (Extended Data Fig. 4c, e ). While such a scenario may be addressed with WNT inhibitor-based therapeutics, the diversity of deregulated Wnt networks in different patients may explain why the notion that targeting high Wnt--catenin signaling in cancer would be universally beneficial has been called into question 32 . P9 and P10 revealed two other scenarios of individual network alterations ( Fig. 3c, d ). Such patient-specific network alteration was also seen for less frequently affected signaling pathways. The PDGF and EGFR pathways were affected seriously in 10 and 7 patients, respectively ( Fig. 4a , e; merged networks of alterations).
However, the scenarios were completely different across individual patients ( Fig. 4 ; Extended Data Fig. 5 ). Important changes were seen in P4 and P5 (Fig. 4b , c) but hardly any in P13 (Fig.   4d ). The same was true for alterations of the EGFR pathway in P5 and P15 ( Fig. 4f , g), while much less nodes were affected in P8 ( Fig. 4h ).
Finally, given that pathways do not act in isolation, we extracted the affected components of several pathways from the "master networks". This analysis showed very clearly that, for P2 and P5 several genes of the Wnt, cadherin and integrin pathways, are shared between two or even three pathways ( Fig. 5) ; the same was observed for other combinations of pathways (Extended Data Fig. 6 ). The functional consequence of deregulation/mutation of such genes is predicted to be serious and such nodes may comprise candidates for therapeutic targeting. It is worth pointing out that also genes at the nexus of several pathways diverged from one patient to another, as shown for P2 and P10 ( Fig. 5a, b ). Indeed, a hypothetical treatment of these two patients -assuming that drugs targeting key components would be available -will have to consider very different scenarios. In the PrCa of P2, common to two or all three pathways, there is a strong upregulation of the expression of several WNT and FZD genes, as well as GSK3B and LEF1. All these factors are potentially druggable and clinical trials are pursued at various levels. In addition, these genes are functionally connected with important other upregulated genes of the Wnt-pathway, such as TP53, MYC, HDAC1 or PPP3CA. For P10, only two FZD genes are overexpressed in cancer and all deregulated WNT genes are less expressed than in the normal prostate tissue of this patient. Moreover, HDAC1 is mutated and MYC is rather repressed. On the other hand, RANBP2 is uniquely overexpressed in P10. Given its multifunctional role as E3-SUMO protein ligase, its overexpression may be an important component of the deregulated network.
Taken together, the patient-centered network analysis we describe here for TMPRSS2-ERG positive primary prostate cancer reveals very divergent patient-specific deregulated and mutated genomic landscapes. This supports a rationale in which therapeutic options are considered in the context of a personalized integrative functional genomics analysis.
In the present case, the affected organs have been surgically removed and with one exception, all patients are still alive. However, we conducted this study as paradigm for other solid cancers where surgery is not possible and for monitoring the development of resistance during therapy.
In addition, there is a growing importance of single cell functional genomics done with circulating tumor cells for diagnosis. Ultimately, additional dimensions, such as chromatin accessibility or RNA regulators such as the newly described circular RNAs 33, 34 , as well as metabolomic changes, may be integrated in this analysis to reveal what communication networks are at the origin, maintenance and progression of the disease and which regulatory circuits can be modulated for therapeutic purposes, including escape from resistance to therapy.
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Correspondence and request for materials should be addressed to H.G. RNA-seq analysis pipeline. The analysis pipeline consists of the following steps. Pre-processing, alignment and counting raw reads. FastQ files were assessed for quality using FastQC. FastQ files were aligned to reference genome (human genome hg19) using the Hisat2 41 aligner.
Figure Legends
Aligned SAM files were converted to BAM files and sorted using SAMtools 38 . The R package SummarizedExperiment 42 was used for counting raw reads per exon/gene.
Differential gene expression analysis. The patient specific differential gene expression analysis was done using DESeq2 (1.20.0) 43 according to the general steps described with the parameters given below. The samples have been analyzed by giving the matched raw read counts normal/tumor duplicates as input. DEseq2 was used to identify the DEGs for each patient. Pathway enrichment analysis was performed in as described before.
Patient-specific network generation and visualization.
To generate the gene networks for individual patients we extracted the list of mutated genes from WES and differentially expressed genes (DEGs) from RNA-seq of tumor vs normal samples for each patient. These lists of genes were queried against two known databases of network interactions, STRING 44 , a Protein-Protein Interaction (PPI) database, and CellNet 7 , a gene regulatory network (GRN) database. For STRING, we merged the list of genes (DEGs and Mutation, keeping the information whether the gene is a DEG or a mutated gene as attributes), removed any duplicated genes and queried them using an in-house script (Supplementary Information). As for the parameters, we only chose edge interactions that have been experimentally validated (exp_score ≠ 0). For CellNet, we queried only the differentially expressed genes on the target genes and retrieved along the cognate transcription factors. We chose interactions who had only a z-score ≥ 5. After obtaining networks from both databases, we proceed to add the information from WES and RNA-seq whether the genes were mutated, differential expressed or both, in addition to the information obtained from the databases.
Network visualization and merging using Cytoscape. Individual networks, created by using
Cellnet and String for each patient, were visualized using Cytoscape 45 . Finally, CellNet and STRING networks for each patient were merged using the Cytoscape merge function to obtain master networks for each patient. Sub-networks were then extracted for further visualization and analysis.
Identification of putative AR and ERG target genes.
A two-step approach was used. First, we collected sequenced read files (bed format) associated to public ChIP-seq assays targeting ERG in TMPRSS2-ERG positive human VCaP prostate cancer (GSM1328978, GSM1328979) and RWPE-1 normal prostate epithelium cells (GSM2195103, GSM2195106). BED Replicate files per cell-type were merged together prior performing peak calling (MACS 1.4; no model, shiftsize=150nts, p-value threshold: 1x10 -5 ), followed by their genomic annotation to the closest transcription start sites (annoPeakR). This analysis allowed to pair the characterized DEGs and mutated genes within the patient-derived networks with genes presenting proximal AR binding sites (<10 kb distance) on VCaP ChIP-seq profiles. This primary analysis has been validated in a second step by comparative visual inspection of ChIP-seq profiles. For this we used the qcGenomics platform (http://ngs-qc.org/qcgenomics/), in which the dedicated genome browser NAVi allows to visualize any publicly available ChIP-seq profile. Specifically, we used NAVi to extract all AR and ERG ChIP-seq profiles for TMPRSS2-ERG positive human VCaP prostate cancer and RWPE1 normal prostate epithelium cells. The pre-computed datasets were displayed simultaneously in the NAVi browser for comparative visualization. Only tracks with an apparent high signal-to-noise ratio were retained (VCaP-ERG: GSM2058880, GSM1328978, GSM1378979, GSM1328980, GSM1328981; VCaP-AR: GSM1410768, RWEP1-ERG: GSM927071, GSM2195110, GSM2195103; VCaP-GROseq: GSM2235682). Promoter-proximal ERG binding was scored positive in this visual 'validation' (attributing a yellow color to the respective nodes) only when there was a clearly visible peak above the background at a scale of 30 to 300 (read count intensity; depending on the signal and noise intensities of each profile), provided that there was no other known TSS closer (see Extended Data Fig. 4 for examples of gain of ERG binding).
Oligonucleotide sequences. Primers used for PCR are specified in Supplementary Table 5 (50) Axon guidance by semaphorins (20) FGF (109) Adenine and hypoxanthine salvage (7) De novo purine biosynthesis (27) Cortocotropin releasing factor receptor (29) 5HT4 type receptor (30) Ionotropic glutamate receptor (44) Vitamin D metabolism (10 ChlP-seq data sets in a and b are from GEO accession numbers (from top to bottom) GSM2058880 (AR, VCaP), GSM1328978 (ERG, VCaP) and GSM927071 (ERG, RWPE-1), as specified. Note that in (a) ERG binding at the HDAC1 promoter is seen in VCaP and RWPE-1 cells, while in (b) for WNT7B a promoter-proximal ERG binding is seen in 'normal' RWPE-1 but not in VCaP cells; this ERG binding site is distant from the AR binding site. The ERG ChlPseq data sets in c, d and e are from GEO accession numbers (from top to bottom) GSM927071 for RWPE-1, GSM1328978 for VCaP (both use anti-ERG antibody Epitomics 2805-1), GSM2195110 for RWPE-1 and GSM2086313 for VCaP. GSM2195110 was done by using Anti-ERG Clone 9FY Biocare # CM421 C, GSM2195110 used an anti-ERG antibody but did not provide the source. Note the consistency between corresponding experiments with different antibodies. 
